Form 4 for UTHR UNITED THERAPEUTICS Corp
Accepted 2022-03-18 00:00:00 ET · period of report 2022-03-17 · accession 0001415889-22-003188 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-18 | 2022-03-17 | UTHR | MAHON PAUL A | EVP, GC | S - Sale+OE | $182.41 | -6,000 | 38.1K | -14% | -$1.09M |
| D | 2022-03-18 | 2022-03-17 | UTHR | MAHON PAUL A | EVP, GC | M - OptEx | $111.00 | +6,000 | 42.5K | +16% | +$666.0K |
| D | 2022-03-18 | 2022-03-17 | UTHR | MAHON PAUL A | EVP, GC | M - OptEx | $0.00 | -6,000 | 52.6K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-17 | S | D | 350 | $184.15 | 36,487 | D | — | — | (F6) This transaction was executed in multiple trades at prices ranging from $183.99 to $184.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2022-03-17 | S | D | 1,281 | $183.25 | 36,837 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $182.75 to $183.6375. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2022-03-17 | S | D | 504 | $181.18 | 41,983 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $180.56 to $181.465. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2022-03-17 | M | A | 6,000 | $111.00 | 42,487 | D | — | — | (F2) Includes 118 shares acquired on March 4, 2022, under the United Therapeutics Corporation Employee Stock Purchase Plan. |
| 5 | Common | Common Stock | 2022-03-17 | S | D | 3,865 | $182.14 | 38,118 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $181.62 to $182.505. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Derivative | Stock Options | 2022-03-17 | M | D | 6,000 | $0.00 | 52,552 | D | $111.00 · 2021-03-15 to 2028-03-15 | 6,000 Common Stock | (F7) These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. |